conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim jul
price data oct
rate updat oct
currenc amount express
methodolog valu compani
oct presid trump outlin potenti action
price drug cover medicar part
administ hospit physician offic
weigh investor sentiment surround government-
led drug price reform announc time
ahead novemb elect follow trump
sign yesterday support bill fight opioid
epidem make fair valu chang
result announc sever signific
uncertainti make difficult assum signific
hit price first remain unclear whether result
actual reform propos industri reaction
comment period run end
could neg smaller fail
effort tweak part price obama
time impact also question demonstr
drug could start would
surpris implement delay beyond trump
first term
increas uncertainti around
implement addit unclear drug would
specif target drug high part
spend similar price intern market see
immuno-oncolog drug ultra orphan diseas
therapi clear geographi would
particip initi demonstr project although
intend cover part spend final
compensatori price increas outsid could help
pharma/big biotech firm signific
exposur medicar part begin discuss
healthcar observ drug price reform
weigh valuat moat look secur drug
biotech industri look under-valued estim
firm highest exposur percentag drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer support care product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first half well neulasta also
face biosimilar threat ophthalmolog drug
regeneron eylea roch lucenti
report highlight trend drug approv
drug spend trump administr start
faster gener brand drug approv rate
also includ analysi support administr
impact price lower rate brand drug price
growth larger discount brand drug sinc earli
bristol-my squibb
sever new piec inform releas today
includ advanc notic propos rulemak
anprm hh report part drug price rel
price develop nation new council
date drug price
anprm follow request inform juli
part larger propos medicar outpati payment
rule allud possibl medicar part
demonstr project anprm discuss potenti
lower part spend save billion six-
year period use intern price
index model base basket intern price
privat sector negoti model would phase
 price five-year period begin spring
focus drug highest part spend
could initi target drug first two year
model one reliabl data intern drug
price target price would lower overal would
vari depend drug price intern market
privat sector negoti competit acquisit
program implement fail think
size part program today could give greater
likelihood success could make part similar
part privat sector negoti via pbm help
control price
today hh report offer detail analysi
intern price highest-sel part
therapi conclud intern price
develop market larg europ canada japan
lower price basket drug
account part spend hh report note
biggest save could seen lower price
rituxan alreadi pois see biosimilar entrant
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
